Customer No. 20,995

Docket No.: OREX.001A

INFORMATION DISCLOSURE STATEMENT

Applicant

Weber, Eckard, et al.

App. No

10/828,795

Filed

April 21, 2004

For

COMPOSITIONS FOR AFFECTING

WEIGHT LOSS

Examiner

Kwon, Brian Yong S.

Art Unit

1614

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 14 references to be considered by the Examiner. Also enclosed are 10 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 6/28/07

By:

Brenden Gingrich

Registration No. 60,295

Attorney of Record

Customer No. 20,995

(619) 235-8550

3945497 062907

10/828,795 Application No. INFORMATION DISCLOSURE Filing Date April 21, 2004 Weber, Eckard First Named Inventor STATEMENT BY APPLICANT 1614 Art Unit Examiner Kwon, Brian Yong S. (Multiple sheets used when necessary) OREX.001A SHEET 1 OF 1 Attorney Docket No.

U.S. PATENT DOCUMENTS									
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear				
	1	6,387,956	05-14-2002	Shapira					
	2	2003-0055038	03-20-2003	Howard					
	3	2003-0130322	07-10-2003	Howard					
	4	2004-0158194	08-12-2004	Wolff, et al.					

	FOREIGN PATENT DOCUMENTS									
Examiner Initials	Çite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹				
	5	WO 94/20100	09-15-1994	Nagle et al.						
	6	WO 03/097046 A1	11-27-2003	Duke University						
	7	WO 2004/024096 A2	03-25-2004	Elan pharma						
	8	WO 2004/100992 A2	11-25-2004	Pfizer						
	9	WO 2004/050020 A2	06-17-2004	Simon, David L.						

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹		
	10	Croft et al., "Effect on body weight of bupropion sustained-release in patients with major depresssion treated for 52 weeks," Clinical Therapeutics 24(4):662-672 (Apr. 2002)			
	11	McDougle, et al., "A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder," Archive of General Psychiatry, 57(8):794-801 August 2000			
	12	Nash et al., "Anxiety disorders," Medicine, 32(7):17-21, July 1, 2004			
	13	Stein, "Neurobiology of the obsessive-compulsive spectrum disorders," Biological Psychiatry 47(4):296-304 February 15, 2000			
	14	Stein, "Obsessive-compulsive disorder," Lancet 360(9330):397-405 August 3, 2002			

3945377 062907

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.